The proposed resolution, titled the "Medical Cannabis Remediation and Testing Rulemaking Approval Resolution of 2025," seeks to amend Subtitle C (Medical Marijuana) of Title 22 (Health) of the District of Columbia Municipal Regulations. This amendment, adopted by the District of Columbia Alcoholic Beverage Control Board on August 28, 2024, allows licensed medical cannabis businesses to remediate products that fail testing for specific reasons that can be addressed without causing harm to patients. The goal of this resolution is to align the District's regulations with those of other jurisdictions and to minimize waste by enabling the repurposing of otherwise unusable medical cannabis products.

The resolution emphasizes the importance of ensuring that medical cannabis products undergo rigorous testing before being provided to patients. It outlines the procedures for remediation, including retesting of remediated batches, and specifies that products failing tests related to pesticides or violations of production standards cannot be remediated. The Council is urged to take prompt action on this resolution, which is designed to enhance the efficiency and sustainability of the medical cannabis program in the District of Columbia.